Jason D. Fontenot - Apr 25, 2022 Form 4 Insider Report for SANGAMO THERAPEUTICS, INC (SGMO)

Signature
Jason D. Fontenot, by /s/ Ron A. Metzger, Attorney-in-Fact
Stock symbol
SGMO
Transactions as of
Apr 25, 2022
Transactions value $
-$3,990
Form type
4
Date filed
4/27/2022, 05:09 PM
Previous filing
Mar 1, 2022
Next filing
Mar 6, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SGMO Common Stock Tax liability -$3.99K -826 -0.79% $4.83* 103K Apr 25, 2022 Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares underlying the portion of a restricted stock unit ("RSU") grant that vested on April 25, 2022 which were surrendered by the Reporting Person to the Issuer for tax withholding using the Issuer's closing stock price on April 25, 2022 of $4.83/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP").
F2 Includes: (a) 2,508 shares resulting from the April 25, 2022 final annual vesting installment of the Reporting Person's April 25, 2019 RSU grant, (b) 8,335 shares subject to the Reporting Person's February 25, 2020 RSU grant that will vest in one final annual installment on February 25, 2023, (c) 14,667 shares subject to the Reporting Person's February 25, 2021 RSU grant that will vest in two remaining annual installments of 7,333 shares and 7,334 shares on February 25, 2023 and 2024, respectively, and (continued in footnote 3)
F3 (d) 45,100 shares subject to the Reporting Person's February 25, 2022 RSU grant that will vest as to one-quarter (1/4) of the shares on the first anniversary of the grant date, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP.